Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 3, 2011, Pages 757-767

  Hudson, Brian D ^a   Beazley, Meggie ^a   Szczesniak, Anna Maria ^a   Straiker, Alex ^b   Kelly, Melanie E M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BETA ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CATECHOLAMINE; LATANOPROST; METOPROLOL; TIMOLOL; TYROSINE 3 MONOOXYGENASE;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE DEPLETION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; WILD TYPE;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC NEURONS; ANIMALS; BENZOXAZINES; CATECHOLAMINES; CIRCADIAN RHYTHM; DRUG EVALUATION, PRECLINICAL; ENDOCANNABINOIDS; EYE; INTRAOCULAR PRESSURE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; NAPHTHALENES; OCULAR HYPOTENSION; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, CANNABINOID; SYMPATHOLYTICS;

EID: 81555207895     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.185769     Document Type: Article

References (41)

1. Akagi Y, Ibata Y, and Sano Y (1976) The sympathetic innervation of the ciliary body and trabecular meshwork of the cat. Fluorescence histochemistry and electron microscopy. Cell Tissue Res 173:261-269.
2. Akaishi T, Odani-Kawabata N, Ishida N, and Nakamura M (2009) Ocular hypotensive effects of anti-glaucoma agents in mice. J Ocul Pharmacol Ther 25:401-408.
3. Alm A and Nilsson SF (2009) Uveoscleral outflow-a review. Exp Eye Res 88:760-768.
4. Alvarado JA, Murphy CG, Franse-Carman L, Chen J, and Underwood JL (1998) Effect of β-adrenergic agonists on paracellular width and fluid flow across outflow pathway cells. Invest Ophthalmol Vis Sci 39:1813-1822. (Pubitemid 28397263)
5. Cervino A (2006) Rebound tonometry: new opportunities and limitations of noninvasive determination of intraocular pressure. Br J Ophthalmol 90:1444-1446.
6. Chien FY, Wang RF, Mittag TW, and Podos SM (2003) Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch Ophthalmol 121:87-90. (Pubitemid 36401772)
7. Civan MM and Macknight AD (2004) The ins and outs of aqueous humour secretion. Exp Eye Res 78:625-631. (Pubitemid 38183341)
8. Colasanti BK, Craig CR, and Allara RD (1984) Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Exp Eye Res 39:251-259. (Pubitemid 15158975)
9. Colasanti BK and Powell SR (1985) Effect of Δ9-tetrahydrocannabinol on intraocularpressure after removal of autonomic input. J Ocul Pharmacol 1:47-57. (Pubitemid 17033148)
10. Crider JY and Sharif NA (2002) Adenylyl cyclase activity mediated by β-adrenoceptorsin immortalized human trabecular meshwork and non-pigmented ciliaryepithelial cells. J Ocul Pharmacol Ther 18:221-230. (Pubitemid 34701298)
11. Ferrer E (2006) Trabecular meshwork as a new target for the treatment of glaucoma.Drug News Perspect 19:151-158.
12. Green K (1979) The ocular effects of cannabinoids. Curr Top Eye Res 1:175-215.
13. Green K, Bigger JF, Kim K, and Bowman K (1977) Cannabinoid action on the eye as mediated through the central nervous system and local adrenergic activity. Exp Eye Res 24:189-196. (Pubitemid 8034652)
14. Green K and Kim K (1976) Mediation of ocular tetrahydrocannabinol effects by adrenergic nervous system. Exp Eye Res 23:443-448.
15. Hepler RS and Frank IR (1971) Marihuana smoking and intraocular pressure. JAMA 217:1392.
16. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology.XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202. (Pubitemid 34575709)
17. Hu SS, Arnold A, Hutchens JM, Radicke J, Cravatt BF, Wager-Miller J, Mackie K,and Straiker A (2010) Architecture of cannabinoid signaling in mouse retina.J Comp Neurol 518:3848-3866.
18. Hudson BD, Hébert TE, and Kelly ME (2010) Physical and functional interactionbetween CB1 cannabinoid receptors and β2-adrenoceptors. Br J Pharmacol 160:627-642.
19. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
20. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, and Kunos G (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023-2028.
21. Järvinen T, Pate DW, and Laine K (2002) Cannabinoids in the treatment of glaucoma.Pharmacol Ther 95:203-220.
22. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
23. Liu JH and Dacus AC (1987) Central nervous system and peripheral mechanisms inocular hypotensive effect of cannabinoids. Arch Ophthalmol 105:245-248. (Pubitemid 17013707)
24. McIntosh BT, Hudson B, Yegorova S, Jollimore CA, and Kelly ME (2007) Agonist dependent cannabinoid receptor signalling in human trabecular meshwork cells.Br J Pharmacol 152:1111-1120. (Pubitemid 350166054)
25. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, and Gelbart SS (1980) Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87:222-228. (Pubitemid 10130590)
26. Nucci C, Bari M, Spanò A, Corasaniti M, Bagetta G, Maccarrone M, and Morrone LA (2008) Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res 173:451-464.
27. Olfe J, Domanska G, Schuett C, and Kiank C (2010) Different stress-related pheno types of BALB/c mice from in-house or vendor: alterations of the sympathetic and HPA axis responsiveness. BMC Physiol 10:2.
28. Oltmanns MH, Samudre SS, Castillo IG, Hosseini A, Lichtman AH, Allen RC,Lattanzio FA, and Williams PB (2008) Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action. J Ocul Pharmacol Ther 24:104-115. (Pubitemid 351156637)
29. 1receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci 63:2181-2188.
30. Piomelli D, Giuffrida A, Calignano A, and Rodríguez de Fonseca F (2000) Theendocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21:218-224.
31. Savinova OV, Sugiyama F, Martin JE, Tomarev SI, Paigen BJ, Smith RS, and John SW (2001) Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet 2:12.
32. Schlicker E, Redmer A, Werner A, and Kathmann M (2003) Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release. Br J Pharmacol 140:323-328. (Pubitemid 37249192)
33. Song ZH and Slowey CA (2000) Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J Pharmacol Exp Ther 292:136-139. (Pubitemid 30026363)
34. Stamer WD, Golightly SF, Hosohata Y, Ryan EP, Porter AC, Varga E, Noecker RJ, Felder CC, and Yamamura HI (2001) Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol 431:277-286. (Pubitemid 33145404)
35. Straiker AJ, Maguire G, Mackie K, and Lindsey J (1999) Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci 40:2442-2448. (Pubitemid 29418406)
36. Stumpff F, Boxberger M, Krauss A, Rosenthal R, Meissner S, Choritz L, Wiederholt M, and Thieme H (2005) Stimulation of cannabinoid (CB1) and prostanoid (EP2)receptors opens BKCa channels and relaxes ocular trabecular meshwork. Exp Eye Res 80:697-708. (Pubitemid 40602971)
37. Szczesniak AM, Kelly ME, Whynot S, Shek PN, and Hung O (2006) Ocular hypotensive effects of an intratracheally delivered liposomal Δ9-tetrahydrocannabino lpreparation in rats. J Ocul Pharmacol Ther 22:160-167. (Pubitemid 44051127)
38. Szczensiak AM, Maor Y, Hung O, Robertson H, and Kelly MEM (2011) Non psychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. J Ocul Pharmacol Ther 27:427-435.
39. Watanabe K and Chiou GC (1983) Action mechanism of timolol to lower the intraocular pressure in rabbits. Ophthalmic Res 15:160-167. (Pubitemid 13028402)
40. Whitney IE, Raven MA, Ciobanu DC, Williams RW, and Reese BE (2009) Multiple genes on chromosome 7 regulate dopaminergic amacrine cell number in the mouse retina. Invest Ophthalmol Vis Sci 50:1996-2003.
41. Woodward DF and Gil DW (2004) The inflow and outflow of anti-glaucoma drugs.Trends Pharmacol Sci 25:238-241. (Pubitemid 38553823)